ETON Eton Pharmaceuticals
Price Chart
Executive Summary
Eton Pharmaceuticals has in-licensed U.S. commercialization rights to HEMANGEOL®, the only FDA-approved treatment for infantile hemangioma, from Pierre Fabre. The acquisition, effective May 1, 2026, adds a commercially available orphan drug to Eton’s portfolio and is expected to be accretive to 2026 earnings, funded with cash on hand.
Actionable Insight
Traders should monitor Eton’s ability to integrate HEMANGEOL into its commercial platform and capitalize on the patient support program to drive uptake. The accretive nature and orphan drug status suggest near-term revenue contribution and margin potential.
Key Facts
- Eton in-licensed U.S. rights to HEMANGEOL® from Pierre Fabre Medicament Sas
- HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma requiring systemic therapy
- Transaction effective May 1, 2026; Pierre Fabre continues global and U.S. commercialization until April 30, 2026
- Expected to be accretive to 2026 earnings
- Financed with company’s cash on hand
- Eton will commercialize via its Eton Cares™ patient support program, including $0 co-pay for qualifying patients
- Approximately 5,000–10,000 infants treated annually in the U.S. with HEMANGEOL
Financial Impact
Accretive to 2026 earnings; exact deal value not disclosed but funded with cash on hand
Risk Factors
- Execution risk in transitioning commercial operations by May 1
- Dependence on specialty distribution and patient support infrastructure
- No disclosed financial terms (e.g., upfront, milestones, royalties) increases uncertainty
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247258 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
16d ago
|
Insider Cluster
| $28.68 $29.13 | ▼ −1.57% | ▼ −4.32% | $31.59 (−10.15%) |
|
May 28, 2026
17d ago
|
144
| $31.86 $27.61 | ▲ +13.34% | ▲ +13.29% | $31.59 (+0.85%) |
|
May 19, 2026
26d ago
|
8-K
| $34.45 $32.40 | ▼ −5.95% | ▼ −7.19% | $31.59 (−8.30%) |
|
Apr 27, 2026
6w ago
|
8-K
| $23.45 $30.16 | ▲ +28.61% | ▲ +28.21% | $31.59 (+34.71%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $23.45 $30.16 | ▲ +28.61% | ▲ +28.21% | $31.59 (+34.71%) |
|
Apr 16, 2026
8w ago
|
8-K
| $24.43 $22.97 | ▼ −5.98% | ▼ −6.96% | $31.59 (+29.31%) |
|
Apr 15, 2026
8w ago
|
8-K
| $24.43 $22.97 | ▼ −5.98% | ▼ −6.96% | $31.59 (+29.31%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $17.53 $18.09 | ▲ +3.19% | ▲ +4.53% | $31.59 (+80.21%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $18.15 $16.70 | ▼ −7.99% | ▼ −6.78% | $31.59 (+74.05%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $18.15 $16.70 | ▼ −7.99% | ▼ −6.78% | $31.59 (+74.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access